A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Complete title: An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses Of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Look up trial at NIH

Research Study Description

Eligibility Criteria (must meet the following to participate in this study)

Keywords: Hematologic Malignancies; Leukemia; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin (NHL); Leukemia, Lymphoid; Immunoproliferative Disorders; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, B-Cell; Lymphoma, Small Lymphocytic (SLL); Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Immune System Diseases; Richter Syndrome; Lymphoma, Marginal Zone

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed